With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…
Make-or-break FDA adcoms beckon for two antibiotics.